Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDAGlobeNewsWire • 07/12/21
4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential24/7 Wall Street • 06/19/21
Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease PatientsBenzinga • 06/11/21
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host DiseaseGlobeNewsWire • 06/11/21
Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of CytometryGlobeNewsWire • 06/10/21
Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic DiseasesGlobeNewsWire • 06/07/21
Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11GlobeNewsWire • 06/03/21
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development UpdateGlobeNewsWire • 05/13/21
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology AssociationGlobeNewsWire • 05/13/21
Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of ImmunologistsGlobeNewsWire • 04/27/21
Equillium's Itolizumab Shows Encouraging Safety, Tolerability Profile In Systemic Lupus Erythematosus StudyBenzinga • 03/31/21
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus PatientsGlobeNewsWire • 03/30/21
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development UpdateGlobeNewsWire • 03/24/21
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow TransplantationGlobeNewsWire • 03/15/21
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital ExperienceGlobeNewsWire • 02/12/21
Equillium Announces the Appointment of Katherine Xu to the Board of DirectorsGlobeNewsWire • 02/09/21
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital ExperienceGlobeNewsWire • 01/22/21